Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
Holding BMEA?
Track your performance easily
BMEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $20.21
Previous CloseN/A
Volume309.16K
Average Volume (3M)1.05M
Market Cap
$147.13M
Enterprise Value$287.44M
Total Cash (Recent Filing)$239.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 03, 2025EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding36,238,686
10 Day Avg. Volume857,488
30 Day Avg. Volume1,049,862
Standard Deviation0.39
R-Squared0.00206
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$24.88Price Target Upside525.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Biomea Fusion News
PremiumCompany Announcements
Biomea Fusion Advances Diabetes Treatment with Positive Study Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D were announced.
Safety And TolerabilityIcovamenib was well-tolerated, with no drug discontinuations due to TEAEs, no hypoglycemic events.
Synergistic EffectsPreclinical studies show that icovamenib enhances insulin secretion when combined with GLP-1-based therapies, suggesting a synergistic effect for improved glycemic control.
Bears Say
Competitive PositionThe AML program is lagging behind primary menin-inhibitor rivals, with RP2D selection anticipated later.
Financial PerformanceThe weak share reaction and anticipation of BMEA trading range bound is influenced by the company's present financing overhang.
Investor SentimentThere is investor skepticism on the mechanism of action and the potential for sustained activity with additional treatment in the commercial setting.
---
Ownership Overview
32.05% Insiders
15.01% Mutual Funds
<0.01% Other Institutional Investors
44.94% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $3.61 and its highest was $20.21 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $147.13M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Oct 29, 2024. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.944 by $0.034.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.91.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 36,238,686 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.944. Following the earnings report the stock price went down -14.262%.
Which hedge fund is a major shareholder of Biomea Fusion?
Among the largest hedge funds holding Biomea Fusion’s share is Baker Bros Advisors LP. It holds Biomea Fusion’s shares valued at 21M.
---
Biomea Fusion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.88 (525.13% Upside)
$24.88 (525.13% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 766.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.47%
12-Months-Change
Fundamentals
Return on Equity
-104.51%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
---
BMEA Stock 12 Month Forecast
Average Price Target
$24.88
▲(525.13% Upside)
Technical Analysis
PMV Pharmaceuticals
―
Keros Therapeutics
―
Relay Therapeutics
―
BioAtla
―
Oric Pharmaceuticals
―
BioMarin Pharmaceutical
―
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-0.86%
reiterated a buy rating 3 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -0.86% per trade.
---